More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Novo Nordisk told Reuters in a statement that a similar dose of Wegovy led to greater weight loss in a 2021 trial and one earlier this year than what was observed in the recent study. The company ...

The statement also said, in part, that "robust data" supporting Wegovy's "meaningful and unique benefits continue to grow" and that in addition to "offering significant and sustained weight loss ...

Wegovy is a once-weekly injection ... calories you should be eating per day to reach your weight loss goals with the Calorie Deficit Calculator. Some foods may aggravate these side effects more ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

The Danish drugmaker Novo Nordisk announced it has temporarily reduced the price of the weight-loss drug Wegovy for new customers as it attempts to limit sales of compounded versions of the ...